Insomnia is not classified as a disease. It is officially classified as a disorder, specifically “insomnia disorder,” in both the DSM-5 (the standard diagnostic manual for mental health conditions) and the ICD-11 (the World Health Organization’s international classification system). The distinction matters: a disease typically implies a specific, identifiable pathological process, while a disorder refers to a disruption of normal function that causes distress or impairment. But make no mistake, insomnia disorder is a recognized, standalone medical condition with measurable biological changes, not just a bad habit or a symptom of something else.
Why the Classification Changed
For decades, insomnia was treated as a secondary problem, something caused by depression, anxiety, chronic pain, or another “real” condition. Under older guidelines, a psychiatrist treating someone with depression and sleep trouble would label the insomnia as a “sleep disorder related to another mental disorder.” The assumption was that fixing the underlying condition would fix the sleep.
That thinking has been abandoned. The DSM-5, published in 2013, deliberately moved away from those causal assumptions. Clinicians are now asked to diagnose insomnia disorder as its own independent condition, even when it occurs alongside depression, anxiety, or a medical illness. This shift happened because research showed that insomnia often persists even after the co-occurring condition is successfully treated. The relationship between insomnia and other health problems runs in both directions: poor sleep worsens depression, and depression worsens sleep, but neither is simply “causing” the other.
What Qualifies as Insomnia Disorder
Not every rough night counts. To meet the diagnostic threshold for chronic insomnia under the ICD-11, sleep difficulties must occur several times per week and persist for at least three months. Symptoms shorter than three months fall under “short-term insomnia,” which is a separate, less severe classification. The core complaint can involve trouble falling asleep, staying asleep, or waking too early, and it must cause noticeable daytime problems like fatigue, difficulty concentrating, or mood disturbance.
By these criteria, chronic insomnia is remarkably common. A 2024 systematic review estimated that roughly 852 million adults worldwide have insomnia, representing about 16.2% of the global adult population. Nearly half of those cases, around 7.9% of all adults, qualify as severe.
What Happens in the Body
Chronic insomnia is not simply a matter of willpower or sleep hygiene. It involves measurable changes in brain chemistry and stress-response systems. The central problem appears to be a state of persistent hyperarousal: your brain’s “wake” systems stay too active, even when you’re exhausted and trying to sleep.
Your brain balances sleep and wakefulness through competing chemical signals. Sleep-promoting chemicals work to quiet the brain, while a set of arousal chemicals (including norepinephrine, serotonin, and orexin) keep it alert. In people with chronic insomnia, this balance tips toward wakefulness. Brain imaging studies have found that people who sleep fewer than six hours per night show lower levels of the brain’s primary calming chemical in key regions of the prefrontal cortex. One study found levels reduced by nearly 30% in people with chronic insomnia compared to healthy sleepers.
The body’s stress system also gets involved. People with chronic insomnia show elevated cortisol levels, particularly in the hours before and just after falling asleep. This reflects overactivation of the hormonal stress pathway connecting the brain to the adrenal glands. The result is a nervous system that stays on alert when it should be powering down. Heart rate variability increases, and levels of norepinephrine, a stress hormone, run higher than normal.
There is also a genetic component. Genome-wide studies estimate that common genetic variants account for about 7% of the variation in insomnia risk, with at least one identified risk region on chromosome 8. That means some people are biologically predisposed to developing the condition, though genetics alone don’t determine whether you’ll have it.
Long-Term Health Risks
Untreated chronic insomnia carries real physical consequences beyond daytime tiredness. The persistent stress-system activation described above directly affects the cardiovascular system over time. People with insomnia have a 45% higher risk of developing cardiovascular disease compared to those without it. When insomnia is combined with very short sleep (under five hours), the risk of hypertension increases further. Men with insomnia who have difficulty falling asleep face a particularly elevated risk of cardiovascular death.
The mechanisms are straightforward: chronic overactivation of stress hormones damages blood vessel lining, raises blood pressure, and keeps the sympathetic nervous system (your “fight or flight” response) running at a higher baseline. Over years, this contributes to coronary disease and heart failure.
The economic toll is substantial as well. A Harvard Medical School study estimated that insomnia costs the average U.S. worker 11.3 lost productivity days per year, worth about $2,280 per person. Nationally, that adds up to $63.2 billion annually.
How It’s Treated
The first-line treatment for chronic insomnia is not medication. The American College of Physicians recommends a structured approach called Cognitive Behavioral Therapy for Insomnia, or CBT-I, as the preferred starting point. This is a short-term therapy, typically lasting four to eight weeks, that addresses the thoughts, behaviors, and habits that keep insomnia going. It includes techniques like restricting time in bed to match actual sleep time, stimulus control (retraining your brain to associate the bed with sleep rather than wakefulness), and restructuring anxious beliefs about sleep.
CBT-I performs as well as sleep medications during the initial treatment period and outperforms them over the long term. Three or more months after treatment ends, people who completed CBT-I maintain their improvements, while those who relied on medication alone typically see benefits fade. Clinical gains from CBT-I have been shown to hold for up to 24 months after the program ends. Despite this evidence, it remains underused, partly because many people don’t know it exists and partly because there aren’t enough trained providers to meet demand.
Sleep medications still play a role for some people, particularly during acute episodes or while waiting to begin CBT-I. But they are not considered the long-term solution for most cases of chronic insomnia disorder.
Disorder, Not Just a Symptom
The reclassification of insomnia as a standalone disorder rather than a symptom of something else was one of the most significant changes in modern sleep medicine. It means that if you’ve been struggling with sleep for months, you aren’t imagining it, and you don’t need to have another diagnosis to justify treatment. Insomnia disorder has identifiable biology, a genetic component, measurable health consequences, and an effective treatment with a strong evidence base. Whether you call it a disease or a disorder is largely a matter of medical terminology. What matters is that it’s real, it’s treatable, and it’s taken seriously.